These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18074583)

  • 1. [Drug-induced thrombocytopenia].
    Hangaishi A; Kurokawa M
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():465-9. PubMed ID: 18074583
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
    Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
    Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal of recurrent thrombocytopenia due to abciximab.
    Sharma V; Mascarenhas D
    J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.
    Rondina MT; Walker A; Pendleton RC
    Hosp Pract (1995); 2010 Apr; 38(2):19-28. PubMed ID: 20469610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
    Mak KH; Kottke-Marchant K; Brooks LM; Topol EJ
    Thromb Haemost; 1998 Dec; 80(6):989-93. PubMed ID: 9869172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia.
    Hayward CP
    Thromb Haemost; 2004 Oct; 92(4):674-5. PubMed ID: 15467893
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
    Rasti M; Blostein M
    Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced immune thrombocytopenia.
    Chong BH; Choi PY; Khachigian L; Perdomo J
    Hematol Oncol Clin North Am; 2013 Jun; 27(3):521-40. PubMed ID: 23714310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombocytopenia associated with c7E3 Fab (abciximab).
    Schell DA; Ganti AK; Levitt R; Potti A
    Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abciximab readministration.
    Orford JL; Holmes DR
    Rev Cardiovasc Med; 2002; 3(2):67-70. PubMed ID: 12447149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro.
    Kozak M; Dovc T; Rozman P; Blinc A
    Wien Klin Wochenschr; 2000 Feb; 112(3):138-41. PubMed ID: 10729966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiosyncratic drug-induced thrombocytopenia.
    Murphy WG; Kelton JG
    Curr Stud Hematol Blood Transfus; 1988; (54):71-88. PubMed ID: 2964994
    [No Abstract]   [Full Text] [Related]  

  • 15. [Thrombocytopenia due to therapeutic drugs].
    Matsuo T; Kario K
    Nihon Naika Gakkai Zasshi; 1993 Jul; 82(7):1024-8. PubMed ID: 8228479
    [No Abstract]   [Full Text] [Related]  

  • 16. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis.
    Warkentin TE
    N Engl J Med; 2007 Mar; 356(9):891-3. PubMed ID: 17329695
    [No Abstract]   [Full Text] [Related]  

  • 20. Fatal delayed thrombocytopenia following abciximab therapy.
    McCorry RB; Johnston P
    J Invasive Cardiol; 2006 Jun; 18(6):E173-4. PubMed ID: 16775895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.